Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy

NCT04132960 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04132960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04132960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
October 21, 2019
Completion date
December 26, 2024
Enrollment
186 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast tumors